Received: 4 January 2022
Accepted: 22 March 2022
First Online: 9 April 2022
: Not applicable. This study has been determined as exempt by the University of Mississippi Institution Review Board.
: Not applicable.
: HMH is funded by Healthcare Services Corporation, a foundation of Blue Cross/Blue Shield, for a study of deprescribing. There is no relationship between the funding and this manuscript under consideration. MS is funded by Handa Oncology, for a study of drug-drug interactions. There is no relationship between the funding and this manuscript under consideration. JMT was formerly a consultant for Takeda Pharmaceutical Company, which is unrelated to this study.